RSPR Pharma’s proprietary lead compound is a new Oral Non-Steroidal Anti-asthmatic (ONSA) for the treatment of early onset allergic asthma. It is scheduled to enter phase I trials later this year and clinical proof of concept trials in 2015. RSPR Pharma is located in Stockholm, Sweden.
Asthma is an inflammatory condition affecting some 300 million people of which about two thirds have early onset allergic asthma. Despite the use of inhaled corticosteroids, only 50% of the patients have adequate asthma control, and the socioeconomic burden of uncontrolled asthma is huge.